IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway
暂无分享,去创建一个
D. Yoon | Ji Young Kim | J. Hong | Jaesuk Yun | R. Mongre | Sukgil Song | S. Han | D. Choi | Yu Ri Kim | Ji Young Kim | Do-Young Yoon | Suk-Young Song | J. Yun | S. Han | Y. Lee | K. Kim | Jin-Tae Hong | Ki Cheon Kim
[1] D. Y. Hwang,et al. IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation , 2018, Cell Death & Disease.
[2] D. Yoon,et al. Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis , 2017, Theranostics.
[3] D. Yoon,et al. Interleukin 32, inflammation and cancer , 2017, Pharmacology & therapeutics.
[4] Zhiqing Liang,et al. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells , 2016, Oncotarget.
[5] N. Sheikh,et al. IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis , 2016, Mediators of inflammation.
[6] D. Yoon,et al. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer , 2016, Oncotarget.
[7] D. Matos,et al. Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival , 2015, PloS one.
[8] J. Snowden,et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.
[9] D. Cheresh,et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. , 2015, Trends in cell biology.
[10] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[11] S. Anand,et al. Abstract 1916: β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition , 2014 .
[12] Yibang Chen,et al. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC , 2014, Apoptosis.
[13] Jing Wang,et al. An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition , 2014, Nature Cell Biology.
[14] Cheng‐Yi Chen,et al. Interleukin-32 Increases Human Gastric Cancer Cell Invasion Associated with Tumor Progression and Metastasis , 2014, Clinical Cancer Research.
[15] D. Yoon,et al. IL‐32γ enhances TNF‐α‐induced cell death in colon cancer , 2014, Molecular carcinogenesis.
[16] R. Clarke,et al. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells , 2013, Breast Cancer Research.
[17] Kai Li,et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. , 2013, Carcinogenesis.
[18] D. Ahn,et al. Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. , 2012, Cancer letters.
[19] D. Yoon,et al. Interleukin‐32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3 , 2012, Immunology.
[20] G. Camussi,et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. , 2011, Journal of the National Cancer Institute.
[21] Fu-xiang Ran,et al. β‐Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells , 2011, Molecular carcinogenesis.
[22] M. Wicha,et al. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.
[23] D. Cheresh,et al. αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.
[24] H. J. Kim,et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals , 2011, Oncogene.
[25] L. Joosten,et al. Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis , 2011, Proceedings of the National Academy of Sciences.
[26] D. Tarin,et al. Abstract 3841: An integrin αvβ3/c-Src oncogenic unit promotes anchorage independence and tumor progression , 2010 .
[27] G. Mills,et al. Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[28] D. Tarin,et al. Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression , 2009, Nature Medicine.
[29] D. Yoon,et al. Identification of the most active interleukin‐32 isoform , 2009, Immunology.
[30] R. Baron,et al. Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases , 2007 .
[31] S. Akira,et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis , 2005, The Journal of experimental medicine.
[32] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[33] P. Foubert,et al. Integrins in Tumor Angiogenesis & Lymphangiogenesis , 2017 .
[34] K. O'Byrne,et al. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. , 2013, Lung cancer.
[35] P. Foubert,et al. Integrins in tumor angiogenesis and lymphangiogenesis. , 2012, Methods in molecular biology.
[36] R. Baron,et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. , 2007, Cancer research.
[37] D. Yoon,et al. Interleukin-32: a cytokine and inducer of TNFalpha. , 2005, Immunity.